Cognitive Therapy for PTSD in Addiction Treatment

This study has been completed.

First Received on May 23, 2008. Last Updated on September 28, 2011 History of Changes

Sponsor:	Dartmouth-Hitchcock Medical Center
Collaborator:	National Institute on Drug Abuse (NIDA)
Information provided by:	Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:	NCT00685451

Purpose

The purpose of this phase of the study is to assess the feasibility of a cognitive behavioral therapy for post-traumatic stress disorder (PTSD) in persons receiving outpatient services at an addiction treatment program. The next phase of the study will be a more rigorous investigation of the efficacy of the PTSD therapy within addiction treatment settings.

Condition	Intervention	Phase
Stress Disorders, Post Traumatic Substance-Related Disorders	Behavioral: Cognitive Behavioral Therapy (CBT)	Phase I Phase II

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Cognitive Therapy for PTSD in Addiction Treatment

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Drug Abuse Post-Traumatic Stress Disorder

U.S. FDA Resources

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:

decrease in substance use at post-therapy and 3 month follow-up
reduction in PTSD symptoms at post-therapy and 3 month follow-up
improvement in addiction treatment retention

Secondary Outcome Measures:

examine impact of depression, anxiety, and borderline personality disorder on outcomes
explore impact of motivation and treatment readiness on outcomes
assess overall level of satisfaction with treatment on outcomes
examine impact of other services received on outcomes

Enrollment:	49
Study Start Date:	November 2004
Study Completion Date:	November 2006
Primary Completion Date:	August 2006 (Final data collection date for primary outcome measure)

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

At least 18 years old;
Actively enrolled in intensive outpatient addiction services;
Diagnosis of PTSD; and
Willing and able to provide informed consent.

Exclusion Criteria:

Acute psychotic disorder;
Psychiatric hospitalization or suicide attempt in the past 2 months;
Known impending court appearance or legal circumstance that may result in incarceration within next 8 months; and
Known medical condition that would likely cause study withdrawal in the next 8 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00685451

Locations

United States, New Hampshire
Fresh Start at Concord Hospital
Concord, New Hampshire, United States, 03301
Farnum Center
Manchester, New Hampshire, United States, 03104
United States, Vermont
Quitting Time
Wilder, Vermont, United States, 05088

Sponsors and Collaborators

Dartmouth-Hitchcock Medical Center

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Mark P. McGovern, Ph.D.

Dartmouth-Hitchcock Medical Center

More Information

No publications provided

Responsible Party:	Mark P. McGovern, Ph.D., Principal Investigator, Dartmouth Medical School
ClinicalTrials.gov Identifier:	NCT00685451 History of Changes
Other Study ID Numbers:	5K23DA016574, 5K23DA016574
Study First Received:	May 23, 2008
Last Updated:	September 28, 2011
Health Authority:	United States: Federal Government

Keywords provided by Dartmouth-Hitchcock Medical Center:

cognitive behavior therapy
addiction
PTSD

Additional relevant MeSH terms:

Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Behavior, Addictive
Substance-Related Disorders

Anxiety Disorders
Mental Disorders
Compulsive Behavior
Impulsive Behavior

ClinicalTrials.gov processed this record on February 09, 2012